Adrian W. Quartel - 29 Jan 2026 Form 4 Insider Report for ZEVRA THERAPEUTICS, INC. (ZVRA)

Role
Chief Medical Officer
Signature
/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Adrian W. Quartel
Issuer symbol
ZVRA
Transactions as of
29 Jan 2026
Net transactions value
-$40,036
Form type
4
Filing time
02 Feb 2026, 17:19:13 UTC
Previous filing
27 Mar 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Quartel Adrian W Chief Medical Officer C/O ZEVRA THERAPEUTICS, INC., 1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION /s/ Timothy J. Sangiovanni, Attorney-in-Fact for Adrian W. Quartel 02 Feb 2026 0001910132

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZVRA Common Stock Options Exercise +11,333 +388% 14,256 30 Jan 2026 Direct F1
transaction ZVRA Common Stock Sale $40,036 -4,533 -32% $8.83 9,723 30 Jan 2026 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZVRA Restricted Stock Unit Award $0 +37,500 $0.000000 37,500 29 Jan 2026 Common Stock 37,500 Direct F1, F4
transaction ZVRA Stock Option (right to buy) Award $0 +75,000 $0.000000 75,000 29 Jan 2026 Common Stock 75,000 $8.86 Direct F5
transaction ZVRA Restricted Stock Unit Options Exercise $0 -11,333 -33% $0.000000 22,667 30 Jan 2026 Common Stock 11,333 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2 Adoption date of referenced 10b5-1(c) plan is: 3/26/2025.
F3 This transaction was executed in multiple trades at prices ranging from $8.62 to $9.04. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 The restricted stock units will vest and settle as to one third of the restricted stock units on January 29, 2027, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting Person's continued service through such vesting date.
F5 Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan. The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.
F6 One third of the restricted stock units vested and settled on January 30, 2026. The remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting Person's continued service through such vesting date.